This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Heron Therapeutics, Inc.
Drug Names(s): APF530, granisetron (sustained release formulation)
Description: Using the Company's proprietary Biochronomer bioerodible drug delivery system, APF530 is designed to provide three to five days of continuous relief from chemotherapy-induced nausea and vomiting following a single subcutaneous injection. APF530 combines A.P. Pharma's Biochronomer drug delivery system with granisetron (Kytril, generically available), one of a class of 5-HT3 antagonists which used for the treatment of nausea and vomiting during and after chemotherapy.
Additional information available to subscribers only: